Acute Ischemic Stroke Clinical Trial
— ASTER2Official title:
Combined Use of Contact Aspiration and the Stent Retriever Technique Versus Stent Retriever Alone for Recanalisation in Acute Cerebral Infarction: the Randomized ASTER2 Study
Verified date | May 2020 |
Source | Hopital Foch |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Mechanical thrombectomy (MT) with a stent retriever (SR) device is now the standard
intervention in ischemic stroke with large vessel occlusion. Favorable outcome is strongly
associated with the successful reperfusion status. New device of MT such as contact
aspiration seems promising to increase reperfusion status and clinical outcome.
The main hypothesis is to show the superiority of combining the use of contact aspiration
with a stent retriever compared to a stent retriever alone in treatment of acute stroke due
to proximal arterial occlusion.
The primary endpoint is the rate of perfect reperfusion score at the end of the endovascular
procedure.
Status | Completed |
Enrollment | 408 |
Est. completion date | February 28, 2020 |
Est. primary completion date | February 28, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Age 18 and older (i.e., candidates must have had their 18th birthday) - Groin puncture carried out within 8 hours of first symptoms - Neuroimaging demonstrates large vessel proximal occlusion (distal ICA through MCA bifurcation, M1 or M2) - Consenting requirements met according to French laws. - With or without intravenous thrombolysis Exclusion Criteria: - Absence of large vessel occlusion on non-invasive imaging - Known or suspected pre-existing (chronic) large vessel occlusion in the symptomatic territory - Suspected pregnancy; if, a woman is of childbearing potential, a urine or serum beta human chorionic gonadotropin (betaHCG) test is positive. - Severe contrast medium allergy or absolute contraindication to iodinated agents. - Patient has severe or fatal comorbidities that will likely prevent improvement or follow-up or that will render the procedure unlikely to benefit the patient. - Acute ischemic stroke involving posterior circulation (vertebrobasilar occlusion) - Angiographic evidence of carotid dissection or tandem cervical occlusion or stenosis requiring treatment. - Patients benefiting from a legal protection - Non-membership of a national insurance scheme - Opposition of the patient or (in case of inclusion as a matter of urgency) of the trustworthy person |
Country | Name | City | State |
---|---|---|---|
France | CHU Bordeaux | Bordeaux | |
France | CHU Limoges | Limoges | |
France | CHU Montpellier | Montpellier | |
France | CHU Nancy | Nancy | |
France | CHU Nantes | Nantes | |
France | Fondation Ophtalmologique Rotschild | Paris | |
France | Kremlin-Bicêtre (APHP) | Paris | |
France | La Pitié-Salpétrière (APHP) | Paris | |
France | Lariboisière (APHP) | Paris | |
France | CHU Rennes | Rennes | |
France | Hôpital Foch | Suresnes |
Lead Sponsor | Collaborator |
---|---|
Hopital Foch |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Perfect reperfusion rate | Perfect reperfusion rate at the end of angiography defined as a Thrombolysis In Cerebral Infarction (TICI) 2c/3 score (TICI score = Thrombolysis In Cerebral Infarction) | 24 hours | |
Secondary | Rate of successful reperfusion | Rate of successful reperfusion (mTICI 2b/2c/3), and complete reperfusion (mTICI3) at end of endovascular procedure | 24 hours | |
Secondary | Rate of perfect (mTICI 2c/3), successful reperfusion (mTICI 2b/2c/3), and complete reperfusion (mTICI3) after the frontline strategy | 24 hours | ||
Secondary | Time from groin puncture to achieve TICI 2c or better revascularization | Time from groin puncture to achieve TICI 2c or better revascularization | 24 hours | |
Secondary | Time between groin puncture to clot contact and clot contact to maximum reperfusion | Time between groin puncture to clot contact and clot contact to maximum reperfusion | 24 hours | |
Secondary | Modified Rankin scale (mRs) | Global disability assessed by overall distribution of mRs at 90-days | 90 days | |
Secondary | Rate of favorable functional independence | Rate of favorable functional independence defined as a mRS 0-2 at 90 days | 90 days | |
Secondary | Rate of excellent functional outcome | Rate of excellent functional outcome defined as a Modified Rankin scale (mRS) 0-1 at 90 days | 90 days | |
Secondary | NIHSS score | Change in NIHSS from baseline to 24 hours (delta NIHSS) | 24 hours | |
Secondary | Rate of symptomatic and asymptomatic intracerebral hemorrhage | Rate of symptomatic and asymptomatic intracerebral hemorrhage at MRI 24h after thrombectomy (according the third European Cooperative Acute Stroke Study (ECASS3) classification) (independent core lab adjudication). | 24 hours | |
Secondary | Rate of parenchymal hematoma | 90 days | ||
Secondary | Rate of all-cause mortality | 90 days | ||
Secondary | Rate of periprocedural complications | - Rate of periprocedural complications: Occurrence of emboli to new territory (ENT), vasospasm, dissection, or perforation. | 90 days | |
Secondary | Average cost per patient | Average cost per patient with complete recanalization | 90 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06113848 -
Adjunctive Use of Intra-Arterial TNK and Albumin Following Thrombectomy
|
Phase 3 | |
Completed |
NCT04069546 -
The Efficacy of Remote Ischemic Conditioning on Stroke-induced Immunodeficiency
|
N/A | |
Active, not recruiting |
NCT05700097 -
Dengzhanxixin Injection for Acute Ischemic Stroke Receiving Reperfusion Therapy
|
Phase 2 | |
Recruiting |
NCT06058130 -
Combination of Antiplatelet and Anticoagulation for AIS Patients Witn Concomitant NVAF and Extracranial/Intracranial Artery Stenosis
|
N/A | |
Recruiting |
NCT04415164 -
Evaluation of Xueshuantong in Patients With AcutE IschemiC STroke
|
Phase 4 | |
Recruiting |
NCT05363397 -
Safety and Tolerability of Adjunctive TBO-309 in Reperfusion for Stroke
|
Phase 2 | |
Completed |
NCT05429658 -
Single Arm Trial to Evaluate the Safety and Effectiveness of the Route 92 Medical Reperfusion System
|
N/A | |
Recruiting |
NCT05390580 -
Neuromodulation Using Vagus Nerve Stimulation Following Ischemic Stroke as Therapeutic Adjunct
|
N/A | |
Enrolling by invitation |
NCT05515393 -
A Study of XY03-EA Tablets in the Treatment of Acute Ischemic Stroke
|
Phase 2 | |
Active, not recruiting |
NCT05070260 -
ACTISAVE: ACuTe Ischemic Stroke Study Evaluating Glenzocimab Used as Add-on Therapy Versus placEbo
|
Phase 2/Phase 3 | |
Terminated |
NCT05547412 -
Validation of Velocity Curvature Index as a Diagnostic Biomarker Tool for Assessment of Large Vessel Stroke
|
||
Completed |
NCT03366818 -
New Stent Retriever, VERSI System for AIS
|
N/A | |
Not yet recruiting |
NCT05293080 -
Early Treatment of Atrial Fibrillation for Stroke Prevention Trial in Acute STROKE
|
Phase 3 | |
Not yet recruiting |
NCT06437431 -
Glenzocimab in Anterior Stroke With Large Ischemic Core Eligible for Endovascular Therapy
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT06040476 -
Human Umbilical Cord Blood Infusion in Patients With Acute Ischemic Stroke (AIS)
|
Phase 2 | |
Completed |
NCT02223273 -
Brazilian Intervention to Increase Evidence Usage in Practice - Stroke (BRIDGE-Stroke)
|
N/A | |
Completed |
NCT02586233 -
Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of DS-1040b in Subjects With Acute Ischemic Stroke
|
Phase 1/Phase 2 | |
Terminated |
NCT01694381 -
Research Into the Effect of a Clot-dissolving Agent and Its Inhibitor
|
Early Phase 1 | |
Not yet recruiting |
NCT01594190 -
Physical Activity Immediately After Acute Cerebral Ischemia
|
N/A | |
Completed |
NCT01120301 -
Efficacy and Safety Trial of Transcranial Laser Therapy Within 24 Hours From Stroke Onset (NEST-3)
|
Phase 3 |